There are provided according to the invention compounds of formula (I)
in free or salt form, wherein
R
1
, R
2
, R
4
, R
5
, R
6
, A, D, X, W, m and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.
cross-coupling reactions by dual nickel/photocatalysis under mild conditions have received considerable attention. However, the existing photo/nickel dual catalytic cross-coupling reactions require the addition of expensive photosensitizers and organic ligands, and the catalytic activity is inadequate. Herein, we report a nickel single-atom heterogeneous catalyst supported on mesoporous carbon nitride for photocatalytic
There is provided an ink set including at least: a yellow ink; a magenta ink; and a cyan ink, in which the yellow ink includes one or more kinds selected from a group consisting of coloring materials represented by the following Formulae (Y-1) and (Y-2), the magenta ink includes one or more kinds selected from a group consisting of coloring materials represented by the following Formulae (M-1) and (M-2), and the cyan ink includes one or more kinds selected from a group consisting of coloring materials represented by the following Formulae (C-1) and (C-2).
APJ RECEPTOR AGONISTS AND USES THEREOF
申请人:AMGEN INC.
公开号:US20160067347A1
公开(公告)日:2016-03-10
The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia, in cardiac disorders such as heart failure.
APELIN POLYPEPTIDES
申请人:AMGEN INC.
公开号:US20170107255A1
公开(公告)日:2017-04-20
The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.